Cell therapy, a relatively new and expensive treatment for certain blood cancers, might soon dislodge a decades-old standard of care for people with a common type of lymphoma that's returned after initial drugs fail.
Results from two late-stage studies, presented over the weekend at the American Society of Hematology's annual conference, showed so-called CAR-T cell therapy decisively outperformed chemotherapy and a stem cell transplant, currently the go-to option for patients whose lymphoma has become resistant or relapsed.
The findings could propel earlier use of CAR-T cell therapies, three of which are approved in the U.S. for later-line treatment of diffuse large B-cell lymphoma, when patients are very sick and have run out of other options.
The Food and Drug Administration is already reviewing an application from Gilead, maker of the CAR-T therapy Yescarta, for an expanded clearance based on the study data presented at ASH Sunday. Bristol Myers Squibb, which sells the competing treatment Breyanzi, could follow using results from its trial, unveiled at the conference Saturday.
"This is a major step forward in the field," said Stephan Grupp, the director of the cancer immunotherapy program at the Children's Hospital of Philadelphia who helped study the third CAR-T therapy available in the U.S., Novartis' Kymriah.
Kymriah didn't prove superior to chemotherapy and a transplant in a similar trial set to be presented at ASH on Tuesday, though differences between study arms and delays in treating patients with the CAR-T therapy could have influenced the results.
The initial approvals of Yescarta, Breyanzi and Kymriah were based on studies without a control group. The trials presented at ASH represent a much stiffer test for CAR-T and could provide evidence for doctors to turn to the treatments sooner.
"These are not easy studies to do," said Grupp. "I think it's fantastic that we actually see randomized data."
Diffuse large B-cell lymphoma, or DLBCL, is the most common form of non-Hodgkin lymphoma. Approximately 18,000 people are diagnosed each year in the U.S., about a third of whom have their cancer relapse or become resistant after initial treatment, typically an antibody drug called Rituxan and chemotherapy.
Once that treatment fails, patients often receive what's known as salvage chemotherapy and, if feasible, a stem cell transplant, which can be curative.
A good number of patients, however, don't respond well enough to chemotherapy to get a transplant, leaving a need for another type of therapy. The study results from Gilead and Bristol Myers suggest CAR-T could fill that void.
Gilead's trial, which began soon after Yescarta's first approval in 2017, included nearly 360 people with refractory or relapsed DLBCL. After following participants for a median of more than two years, researchers reported Sunday that treatment with Yescarta significantly extended what's known as event-free survival the time until cancer progression, subsequent treatment or death from any cause.
Participants given Gilead's drug went a median of 8.3 months without an "event," compared to 2 months for those assigned to standard of care a risk reduction of about 60%. Additionally, more study volunteers responded and went into remission after receiving Yescarta than did those in the control group.
Follow-up is still ongoing to determine exactly how long Yescarta recipients survived following treatment, although it's at least longer than 28 months, based on statistical estimates. Results were also published in The New England Journal of Medicine.
The story was similar in Bristol Myers' study, which began more recently and enrolled 184 participants with a similar stage of lymphoma. Patients were event-free for a median of 10 months with Breyanzi, a 65% risk reduction compared to chemotherapy and a transplant. Rates of response and remission were about the same as what was observed in Gilead's study of Yescarta.
*Standard second-line treatment is chemotherapy followed by a stem cell transplant SOURCE: Companies, ASH abstracts and presentations
Only about a third to nearly half of volunteers assigned to standard treatment in the two studies actually received a stem cell transplant, highlighting the difficulties in getting patients to that point.
The two studies show CAR-T therapy may "negate the need for high-dose chemo and autologous stem cell transplant in some patients," said Tanya Siddiqi, an oncologist and associate professor in the lymphoma division at the City of Hope, in an email.
Yet CAR-T also comes with notable side effects, most significantly a potentially overwhelming immune response known as cytokine release syndrome as well as neurotoxicity.
On that score, Breyanzi appeared to cause fewer severe reactions. Only one participant experienced cytokine release syndrome classified as Grade 3, and just 4% experienced a similar level of neurological side effects. Treatment with Yescarta, by comparison, led to Grade 3 cytokine release syndrome in 6% of patients and Grade 3 neurotoxicity in 21%.
Both CAR-T therapies carry warnings from the FDA for those side effects in their approved later-line treatment setting.
Multiple factors affect CAR-T safety and, while Yescarta and Breyanzi home in on the same cancer cell target, they are constructed differently. Bristol Myers, whose drug got to market later than Gilead's, claims Breyanzi's safety profile can help it compete.
The results are "not only favorable in terms of efficacy, but also encouraging in terms of safety," said Anne Kerber, Bristol Myers' head of cell therapy development. "We really believe it is going to be practice changing."
Even if the results presented at ASH lead to future FDA approvals, CAR-T therapy remains an expensive and complicated treatment. Yescarta costs $373,000; Breyanzi about 10% more at $410,300 extremely high prices meant to reflect the possibility they could deliver long-lasting benefits.
Insurance coverage has improved over time, helped by national policies put in place by Medicare and Medicaid in 2019, but broader use could rekindle the debate over whether CAR-T is cost-effective.
CAR-T therapies are also custom-made for each patient, built on immune cells extracted from the body and engineered in a laboratory to seek out tumors. The manufacturing process, measured from when cells are extracted to when they are reinfused, takes a little more than two weeks for Yescarta and just over three weeks for Breyanzi.
Since launching Breyanzi earlier this year, Bristol Myers has said that it has met its turnaround target of 24 days approximately 90% of the time.
The studies of second-line CAR-T treatment "leave other important unanswered questions for the many patients who can't wait for CAR-T cell manufacturing without second-line chemotherapy and remain chemosensitive," said Alex Herrera, an oncologist at City of Hope, in a Sunday discussion of Gilead's results at ASH.
Doctors will also be eager to see how many patients who respond to CAR-T remain in remission over time, and how much longer they live than those who receive transplants.
Note: This story has been updated with additional comment.
Go here to see the original:
CAR-T therapy trials show promise for earlier use in lymphoma - BioPharma Dive
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 15th, 2024
- Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML - Medpage Today - February 15th, 2024
- Drug used for cocaine addiction may pave way for new treatment of advanced colon cancer - EurekAlert - February 15th, 2024
- Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - February 15th, 2024
- Biomedical Researcher Seeks to Improve Outcomes in Stem Cell Treatments - University of Arkansas Newswire - February 13th, 2024
- Top 3 grants in regenerative medicine: January 2024 - RegMedNet - February 13th, 2024
- Scalise returning to Washington next week with cancer in complete remission - The Hill - February 13th, 2024
- Unlocking the power of stem cell therapy - Drug Target Review - February 9th, 2024
Recent Comments